TNF and heart failure: In the POSEIDON-DCM trial, allogenic MSC treatment showed significantly more improvement in 6MWT and the Minnesota Living with Heart Failure Questionnaire (MLHFQ), compared to autologous MSCs, and a lower rate of major adverse cardiac events (MACEs) and lower levels of tumour necrosis factor α (TNFα).